• Lawrence Blonde.
• Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Diabetes and Metabolism, Ochsner Medical Center, New Orleans, Louisiana 70121, USA. lblonde@ochsner.org
• Am. J. Med. 2010 Mar 1; 123 (3 Suppl): S12S18S12-8.

AbstractType 2 diabetes mellitus and obesity are associated with increased cardiovascular risk. While lifestyle interventions such as medical nutrition therapy and appropriately prescribed physical activity remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. Fortunately, many of these patients are able to achieve desired glycemic targets with the use of currently available antihyperglycemic agents. Both not-for-profit disease-specific organizations and healthcare specialty societies have provided guidance about the appropriate selection of these therapies. Type 2 diabetes treatment guidelines and algorithms have been developed, taking into account a combination of evidence-based information and expert opinions, with various groups offering diverse glucose goals and approaches to hyperglycemia management. Virtually all recognize that type 2 diabetes is a multifaceted disease, necessitating an integrated yet individualized approach to patient care.(c) 2010. Published by Elsevier Inc.

22 keywords...

hide…